Şunu aradınız:: zoledronatne (Hırvatça - İngilizce)

4,0 mg zoledronatne kiseline
4.0 mg zoledronic acid

preporučena doza zoledronatne kiseline
zoledronic acid recommended dose*

koliko se zoledronatne kiseline teva daje
how much zoledronic acid teva is given

4 mg zoledronatne kiseline (n=86)
zoledronic acid 4 mg (n=86)

koliko se zoledronatne kiseline accord daje
how much zoledronic acid accord is given

koliko se zoledronatne kiseline hospira primjenjuje
how much zoledronic acid hospira is given

jedna boca sadrži 4 mg zoledronatne kiseline.
one bottle contains 4 mg zoledronic acid.

jedna bočica sadrži 4 mg zoledronatne kiseline.
one vial contains 4 mg of zoledronic acid.

koje su koristi i rizici zoledronatne kiseline teva?
what are the benefits and risks of zoledronic acid teva?

ako primite više zoledronatne kiseline teva nego što ste trebali
if you are given more zoledronic acid teva than you should be

ako primite više zoledronatne kiseline accord nego što ste trebali
if you are given more zoledronic acid accord than you should be

nema odgovarajućih podataka o primjeni zoledronatne kiseline u trudnica.
there are no adequate data on the use of zoledronic acid in pregnant women.

ako ste primili više zoledronatne kiseline actavis nego što ste trebali
if you are given more zoledronic acid actavis than you should be

djelatna tvar zoledronatne kiseline teva, zoledronatna kiselina, je bisfosfonat.
the active substance in zoledronic acid teva, zoledronic acid, is a bisphosphonate.

bolesnici moraju biti prikladno hidrirani prije primjene zoledronatne kiseline.
patients must be appropriately hydrated prior to administration of zoledronic acid.

1 boca sadrži 4 mg zoledronatne kiseline (u obliku hidrata).
1 bottle contains 4 mg zoledronic acid, (as monohydrate).

bolesnici moraju biti prikladno hidrirani prije primjene zoledronatne kiseline hospira.
patients must be appropriately hydrated prior to administration of zoledronic acid hospira.

jedna bočica sadrži 4 mg zoledronatne kiseline (u obliku hidrata)
one vial contains 4 mg of zoledronic acid (as monohydrate)

hipokalcemija je važan indentificirani rizik u primjeni zoledronatne kiseline u odobrenim indikacijama.
hypocalcaemia is an important identified risk with zoledronic acid in the approved indications.

svaki ml otopine sadrži 0,05 zoledronatne kiseline (u obliku hidrata).
each ml of the solution contains 0.05 mg zoledronic acid (as monohydrate).